Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. - Wikidata - awgldk - TriplyDB

Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke.

Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke.

http://www.wikidata.org/entity/Q33793559

about

Neural Plasticity in Multiple Sclerosis: The Functional and Molecular Background Fingolimod for the treatment of neurological diseases-state of play and future perspectives Role of cannabinoids in multiple sclerosis CB1 and CB2 Cannabinoid Receptor Antagonists Prevent Minocycline-Induced Neuroprotection Following Traumatic Brain Injury in Mice Simvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice.Neuroprotective therapies after perinatal hypoxic-ischemic brain injury.CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model.The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells.Cannabinoid receptor type 2 agonist attenuates apoptosis by activation of phosphorylated CREB-Bcl-2 pathway after subarachnoid hemorrhage in rats.Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury.HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions.Endocannabinoids and traumatic brain injury Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury Effects of Cannabinoids on T-cell Function and Resistance to Infection.Differential migratory properties of monocytes isolated from human subjects naïve and non-naïve to Cannabis.Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions A CB2-Selective Cannabinoid Suppresses T-Cell Activities and Increases Tregs and IL-10 Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line IV and IP administration of rhodamine in visualization of WBC-BBB interactions in cerebral vessels Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors.A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression.The analgesic potential of cannabinoids.G protein-coupled receptors as therapeutic targets for multiple sclerosis.From recreational to functional drug use: the evolution of drugs in American higher education, 1960-2014.Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation.Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction.Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS The multiplicity of action of cannabinoids: implications for treating neurodegeneration.Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier.Using the endocannabinoid system as a neuroprotective strategy in perinatal hypoxic-ischemic brain injury.Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.The CB1 antagonist, SR141716A, is protective in permanent photothrombotic cerebral ischemia.Lauroylethanolamide is a potent competitive inhibitor of lipoxygenase activity.A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury.Immune-modulation and properties of absorption and blood brain barrier permeability of 1,8-naphthyridine derivatives.

P2860

Q26801046-0CD9AFDD-9C22-4403-9CB7-4591E1328046 Q27026175-B59B914B-F5BA-4D93-B615-121441A56B7A Q28305413-E23B91EF-4C80-4A63-A4F7-31EC48A33F48 Q28315817-E4DFC243-E84E-4721-84EB-64E9038A7230 Q33725859-CBA80BEC-A980-41D7-B671-F7F5FDCF1B2D Q33772042-F82E2181-D6FD-4CFC-9672-0AE486FDD4C2 Q34098258-3CD97CD9-BE2A-42D5-8429-93965DF3CAE2 Q34098266-A9CC26D2-D972-44C7-8787-F74740BF009C Q34098271-379359D5-4243-4BE6-BE18-DDE222820CA9 Q34325190-4EF6F31F-3F37-4EE8-ABCD-C875E54A5DBB Q34591087-644EAA4D-E850-4F5D-99C0-7D89B307EC1F Q34993393-C5C7FB05-1009-45C9-910C-B99853D65F58 Q35193282-2CE677E2-C01F-48E1-8E53-6CCD7A9C134F Q35589934-11E45FB2-6077-47A5-9831-6B264485F332 Q35606180-81387D0F-5323-4B7E-A9C5-61D3DCE53AB9 Q35752185-A94CA3E0-1447-46F6-87FB-E37B7A72A363 Q35766665-66EBC537-57AD-493A-9369-BC1A40D6C6FC Q35887816-AD538D3D-921A-444F-9A31-08F706C1B022 Q35927832-E352098A-82D0-4B7D-AD2E-9344BE48E87D Q36032332-B683F858-F76E-49EA-9EA0-1F01A759C25C Q36090228-7F6FBA5A-F15E-4FE5-BA77-59109A709990 Q36176486-8BD4CBB5-2C3B-4368-8D60-8DC96222EF55 Q36176499-3AE3EAD5-1002-4C36-B962-6201FBD3A411 Q36370835-BFFDE315-4006-4C72-8735-912FC2D79CD7 Q37057325-B6FA8714-2E94-45DA-B7DA-D8F196795705 Q37112554-AB9B07F6-E2AE-4D2A-909B-26A10997640B Q37149588-F4D7C2A7-24D8-4DE3-9954-F8157E4913F4 Q37216210-169FE475-6C14-4ECD-B758-09AFC138A444 Q37396781-6E1CA5BB-CAF7-40B2-9263-39F8362BA548 Q37531460-56A967AE-E264-4106-A4C8-0DE34B685F65 Q37793366-625B1775-715D-4D7A-8803-73B0C590126C Q38220272-488562B1-C145-460E-BA4E-AC0D254C91C5 Q38248001-FD5F6111-62A8-4B8E-A653-84B6E0907D48 Q38520997-0047AB1C-BE69-411D-9B67-140057D7E620 Q38563981-2FA261BC-AD7E-435C-9564-B588511C35A4 Q38684679-B37E052E-AA53-4C06-8196-C44F0FEFB98B Q40961956-6E01FDB3-BDE2-49A2-A97C-32D0E5217482 Q43028655-B2C082AF-48B6-406B-A9E7-4E1E44AC6486 Q47965888-14AD1FBD-AB38-4E33-9852-E388CAD071AB Q48965109-118E9E3C-CCA5-422B-8CAA-F24310EE5997

P2860

Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke.

http://www.wikidata.org/entity/Q33793559

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Modulation of cannabinoid rece ...... e strategy for EAE and stroke.

@ast

Modulation of cannabinoid rece ...... e strategy for EAE and stroke.

@en

type

label

Modulation of cannabinoid rece ...... e strategy for EAE and stroke.

@ast

Modulation of cannabinoid rece ...... e strategy for EAE and stroke.

@en

prefLabel

Modulation of cannabinoid rece ...... e strategy for EAE and stroke.

@ast

Modulation of cannabinoid rece ...... e strategy for EAE and stroke.

@en

P1433

Q33793559-093F8519-40FB-4315-B92C-FDFC8390C762

P1476

Q33793559-9A5B071A-C8F6-4341-9A72-E03ED3BFDF99

P2093

Q33793559-2D31734E-3B87-48C3-8C24-0A1D38135D1D

Q33793559-3C6A7647-3EC0-47BB-B3ED-0BEFDDE0B063

Q33793559-52E3452E-7207-4441-A805-B89B5A435C2B

Q33793559-54D545DA-8E4A-4DC3-A115-D21ADC91F2CD

Q33793559-67B6CCF9-5542-475E-9222-B0082A6A68B1

Q33793559-7AE7E16B-6CBB-4D1F-AEE0-76A86F357F54

Q33793559-7B6D5964-8D2A-4838-B6C5-6F25C95EC718

P2860

Q33793559-04397088-11D4-4756-845A-874CF4BA26E2

Q33793559-112B6A50-4FEA-49E7-A7EE-683710F4EE4C

Q33793559-196408B9-6872-4056-8144-2017DE99D3DC

Q33793559-1D890BE9-B314-4820-979E-AC5378143CE7

Q33793559-1DE71B66-A531-482B-A411-9EDD70F940E0

Q33793559-1DEAE70C-5070-4045-89CD-2A5C3DD729C0

Q33793559-31B10C09-7E9C-4525-8EF1-136FDD06194A

Q33793559-330C9E75-E9ED-4BC2-8F44-BE415D9C7ECF

Q33793559-39BBC169-14F2-485E-A179-47BA30243093

Q33793559-3D7D6A90-A41B-4B5A-98B4-70F531806004

P2888

Q33793559-D28710E2-B918-4CD0-85C9-7DF8AC1AF5DF

P304

Q33793559-0472CFAF-CBF4-4727-88A5-4F53F0969B38

P31

Q33793559-8E53E7A8-B6FF-455C-B6E5-6103A7FEFA54

P356

Q33793559-3D2924F8-FF8F-4074-8608-9C14F09B65DC

P433

Q33793559-7E443B1F-E6F5-4603-816E-42628E10B2CA

P478

Q33793559-2B274E58-89FE-45AE-80D1-8ED10690D57F

P577

Q33793559-045E7056-461A-401C-8813-F35729F09E48

P5875

Q33793559-33809B20-C6B3-42E1-BFF0-FB0756CB5380

P6179

Q33793559-6A1ABF8D-A399-4EBD-A536-68756B60B960

P698

Q33793559-1D8B7C91-83A3-47F9-BAD2-D34B41A4626F

P921

Q33793559-A3259A10-75C0-4A87-A085-40C165A6459B

Q33793559-EAAAFA36-2961-4E15-B114-9D9A305C8F43

Q33793559-efafb38d-99c6-4040-9009-e4d520101be7

P932

Q33793559-9AB56763-4046-4E8D-A93C-D8A9DFE558B3

P356

S11481-009-9148-4

P1433

Journal of Neuroimmune Pharmacology

P1476

Modulation of cannabinoid rece ...... e strategy for EAE and stroke.

@en

P2093

Billy R Martin

http://www.w3.org/2001/XMLSchema#string

Doina Ganea

http://www.w3.org/2001/XMLSchema#string

Martin W Adler

http://www.w3.org/2001/XMLSchema#string

Ming Zhang

http://www.w3.org/2001/XMLSchema#string

Raj J Razdan

http://www.w3.org/2001/XMLSchema#string

Ronald F Tuma

http://www.w3.org/2001/XMLSchema#string

Weimin Kong

http://www.w3.org/2001/XMLSchema#string

P2860

Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors

The endocannabinoid system as an emerging target of pharmacotherapy

Cannabinoids control spasticity and tremor in a multiple sclerosis model

Endocannabinoids control spasticity in a multiple sclerosis model

Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA)

Pharmacology and stereoselectivity of structurally novel cannabinoids in mice

Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity.

Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo.

Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system.

Cannabinoid receptors as therapeutic targets.

P2888

s11481-009-9148-4

P304

249-259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11481-009-9148-4

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24172209

http://www.w3.org/2001/XMLSchema#string

P6179

1051857882

http://www.w3.org/2001/XMLSchema#string

P698

19255856

http://www.w3.org/2001/XMLSchema#string

P921

cannabinoid receptor

P932

2855650

http://www.w3.org/2001/XMLSchema#string